131 related articles for article (PubMed ID: 2272030)
1. New cytostatics--more activity and less toxicity.
Berger MR; Richter H; Seelig MH; Eibl H; Schmähl D
Cancer Treat Rev; 1990 Sep; 17(2-3):143-54. PubMed ID: 2272030
[No Abstract] [Full Text] [Related]
2. Tumor heterogeneity and chemosensitivity to cyclophosphamide, vinblastine and hexadecylphosphocholine.
Angres G; Scherf HR; Schmähl D
Cancer Treat Rev; 1990 Sep; 17(2-3):339-45. PubMed ID: 2272049
[No Abstract] [Full Text] [Related]
3. Hexadecylphosphocholine: a new and selective antitumor drug.
Eibl H; Unger C
Cancer Treat Rev; 1990 Sep; 17(2-3):233-42. PubMed ID: 2272038
[TBL] [Abstract][Full Text] [Related]
4. Alkyl phosphocholines: toxicity and anticancer properties.
Muschiol C; Berger MR; Schuler B; Scherf HR; Garzon FT; Zeller WJ; Unger C; Eibl HJ; Schmähl D
Lipids; 1987 Nov; 22(11):930-4. PubMed ID: 3444388
[TBL] [Abstract][Full Text] [Related]
5. Effect of miltefosine on transplanted methylnitrosourea-induced mammary carcinoma growing in Fischer 344 rats.
Reinhardt M; Heyl P; Amelung F; Berger MR
Arzneimittelforschung; 1992 Oct; 42(10):1239-42. PubMed ID: 1282010
[TBL] [Abstract][Full Text] [Related]
6. New pharmaceuticals: miltefosine.
Hilgard P
Anticancer Drugs; 1990 Dec; 1(2):185. PubMed ID: 2131052
[No Abstract] [Full Text] [Related]
7. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo.
Sobottka SB; Berger MR; Eibl H
Int J Cancer; 1993 Feb; 53(3):418-25. PubMed ID: 8428795
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas.
Berger MR; Yanapirut P; Reinhardt M; Klenner T; Scherf HR; Schmeiser HH; Eibl H
Prog Exp Tumor Res; 1992; 34():98-115. PubMed ID: 1438807
[No Abstract] [Full Text] [Related]
10. Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.
Kaufmann-Kolle P; Berger MR; Unger C; Eibl H
Adv Exp Med Biol; 1996; 416():165-8. PubMed ID: 9131143
[No Abstract] [Full Text] [Related]
11. Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.
Scherf HR; Schuler B; Berger MR; Schmähl D
Lipids; 1987 Nov; 22(11):927-9. PubMed ID: 3444387
[TBL] [Abstract][Full Text] [Related]
12. New cytostatics with experimentally different toxic profiles.
Berger MR; Muschiol C; Schmähl D; Eibl HJ
Cancer Treat Rev; 1987 Dec; 14(3-4):307-17. PubMed ID: 3440252
[No Abstract] [Full Text] [Related]
13. The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.
Cain BF; Atwell GJ
Eur J Cancer (1965); 1974 Aug; 10(8):539-49. PubMed ID: 4463003
[No Abstract] [Full Text] [Related]
14. In vitro and in vivo antitumoral activity of alkylphosphonates.
Ries UJ; Fleer EA; Breiser A; Unger C; Stekar J; Fenneberg K; Eibl H
Eur J Cancer; 1992; 29A(1):96-101. PubMed ID: 1445752
[TBL] [Abstract][Full Text] [Related]
15. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Unger C; Damenz W; Fleer EA; Kim DJ; Breiser A; Hilgard P; Engel J; Nagel G; Eibl H
Acta Oncol; 1989; 28(2):213-7. PubMed ID: 2736110
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine.
Kaufmann-Kolle P; Drevs J; Berger MR; Kötting J; Marschner N; Unger C; Eibl H
Cancer Chemother Pharmacol; 1994; 34(5):393-8. PubMed ID: 8070005
[TBL] [Abstract][Full Text] [Related]
17. D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
Hilgard P; Klenner T; Stekar J; Nössner G; Kutscher B; Engel J
Eur J Cancer; 1997 Mar; 33(3):442-6. PubMed ID: 9155530
[TBL] [Abstract][Full Text] [Related]
18. Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium.
Theischen M; Bornfeld N; Becher R; Kellner U; Wessing A
Ger J Ophthalmol; 1993 Apr; 2(2):113-5. PubMed ID: 8485436
[TBL] [Abstract][Full Text] [Related]
19. Experimental research in the influence of the endocrine status on the antiblastic activity of cytostatics.
Zimel H
Neoplasma; 1967; 14(4):345-52. PubMed ID: 6063010
[No Abstract] [Full Text] [Related]
20. Effect of medroxyprogesterone acetate and doxorubicin on sublines of 13762 mammary adenocarcinoma in rats.
Formelli F; Zaccheo T; Casazza AM; Bellini O; Di Marco A
Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1211-21. PubMed ID: 6460631
[No Abstract] [Full Text] [Related]
[Next] [New Search]
